Clinical trial NCT06561386 · Non-small Cell Lung Cancer
Oncology research
26 Oct 2026
NCT06561386 — is «recruiting» on ClinicalTrials.gov.
Clinical trial NCT06561386 (phase III) is «recruiting» on ClinicalTrials.gov.
Condition: Non-small Cell Lung Cancer · Registered interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin · Recorded dates (source): 2024-10-07, 2030-07-30, 2024-08-20, 2026-10-23.
Study summary (source: ClinicalTrials.gov):
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%